Clinical Trials

Find a Trial

Trial Results

14 protocol(s) meet the specified criteria
1205-201OPEN TO ACCRUAL
A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
B-016-001OPEN TO ACCRUAL
Clinical Assessment of Intraoperative Nerve Monitoring during Robot-assisted Laparoscopic Prostatectomy
C16-168OPEN TO ACCRUAL
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects
CTMX-M-2009-001OPEN TO ACCRUAL
A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors
GCP-10100OPEN TO ACCRUAL
Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients with Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study
GU115/I6A-MC-CBBDOPEN TO ACCRUAL
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer
IUSCC-0523OPEN TO ACCRUAL
Perioperative pelvic floor muscle training may improve recovery of continence in men with localized prostate cancer undergoing robot-assisted radical prostatectomy.
IUSCC-0584OPEN TO ACCRUAL
COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY FOR THE GENITOURINARY ONCOLOGY PROGRAM
IUSCC-0588OPEN TO ACCRUAL
Glycosylation of exosomes in prostate and urothelial carcinoma
IUSCC-0614OPEN TO ACCRUAL
A pilot feasibility study of sipuleucel-T vs. sipuleucel-T and low-protein diet in patients with metastatic castrate-resistant prostate cancer (CRPC)
IUSCC-0634OPEN TO ACCRUAL
Detection of single nucleotide variants in circulating tumor DNA of patients with metastatic castration resistant prostate cancer
NRG-GU002OPEN TO ACCRUAL
PHASE II-III TRIAL OF ADJUVANT RADIOTHERAPY AND ANDROGEN DEPRIVATION FOLLOWING RADICAL PROSTATECTOMY WITH OR WITHOUT ADJUVANT DOCETAXEL
RADY-FIVEELEVEN-GREEN-GAOPEN TO ACCRUAL
Biodistribution and dosimetry of the investigational PET agent 68Ga-P16-093 in prostate cancer patients with biochemical recurrence undergoing clinical 68Ga-PSMA-11 PET/CT
STU00077147OPEN TO ACCRUAL
Impact of Genetic Variants on Failure of Active Surveillance for Prostate Cancer